FrankAccursoMD
Pediatric Pulmonology • Aurora, COProfessor, Pediatrics, University of Colorado School of Medicine
Are you Dr. Accurso?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 55 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
13123 E 16th Ave
Aurora, CO 80045Phone+1 720-777-1234
Summary
- Dr. Frank Accurso, MD is a pediatric pulmonologist in Aurora, Colorado. He is currently licensed to practice medicine in Colorado. He is affiliated with University of Colorado Hospital and Children's Hospital Colorado.
Education & Training
University of ColoradoFellowship, Pulmonary Disease and Critical Care Medicine, 1978 - 1979- University of ColoradoResidency, Pediatrics, 1974 - 1977
Albert Einstein College of MedicineClass of 1974
Certifications & Licensure
CO State Medical License 1977 - 2019- American Board of Pediatrics Pediatrics
Clinical Trials
- Airway Secretion Clearance in Cystic Fibrosis Start of enrollment: 1999 Dec 01
- Sweat Evaporimeter Measurement Start of enrollment: 2011 Dec 01
- Study of Ataluren in Nonsense Mutation Cystic Fibrosis (ACT CF) Start of enrollment: 2014 Aug 01
Publications & Presentations
PubMed
- 6 citationsEntering the era of highly effective CFTR modulator therapyEdith T. Zemanick, Frank J. Accurso
Lancet. 2019-11-23 - 13 citationsNovel Application of Aptamer Proteomic Analysis in Cystic Fibrosis Bronchoalveolar Lavage Fluid.Emily M. DeBoer, Brandie D. Wagner, Jonathan Popler, J.K. Harris, Edith T. Zemanick
Proteomics. Clinical Applications. 2019-05-01 - 13 citationsA multicenter evaluation of sweat chloride concentration and variation in infants with cystic fibrosis.Vicky A. LeGrys, Tara C. Moon, J. Laux, Frank J. Accurso, S. A. Martiniano
Journal of Cystic Fibrosis. 2019-03-01
Press Mentions
An Open-Label Extension Study of Ivacaftor in Children with CF and a CFTR Gating Mutation Initiating Treatment at Age 2-5 Years (KLIMB)November 1st, 2019
Novel Drug Offers Hope for Early Intervention in Cystic Fibrosis PatientsDecember 17th, 2010
Redefining Disease, Genes and AllMay 6th, 2008- Join now to see all
